Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Fineline Cube Feb 12, 2026
Company Deals

Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs

Fineline Cube Feb 12, 2026
Company Deals

Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Fineline Cube Feb 12, 2026
Company Drug

Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer

Fineline Cube Feb 12, 2026
Company Drug

Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial

Fineline Cube Jun 27, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline...

Company Drug

Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter

Fineline Cube Jun 27, 2024

Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...

Company Drug

Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide

Fineline Cube Jun 27, 2024

Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...

Company Deals

CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development

Fineline Cube Jun 27, 2024

CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of...

Company Drug

J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns

Fineline Cube Jun 26, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...

Company Drug

AstraZeneca’s Tagrisso Wins NMPA Approval for First-Line EGFR-mutated NSCLC Treatment

Fineline Cube Jun 26, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, has announced that it has received another...

Company Deals

Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit

Fineline Cube Jun 26, 2024

Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer...

Policy / Regulatory

China’s NMPA Proposes Expedited Review for Clinically Urgent Overseas Drugs

Fineline Cube Jun 26, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement of the...

Company Deals Digital R&D

Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery

Fineline Cube Jun 26, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company Deals

Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%

Fineline Cube Jun 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...

Company Drug

Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Jun 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...

Company Drug

CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval

Fineline Cube Jun 26, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval

Fineline Cube Jun 26, 2024

Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...

Company Drug

Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux

Fineline Cube Jun 26, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...

Company Deals

Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences

Fineline Cube Jun 26, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Policy / Regulatory

U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India

Fineline Cube Jun 25, 2024

U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...

Company

Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion

Fineline Cube Jun 25, 2024

Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...

Company Drug

Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial

Fineline Cube Jun 25, 2024

Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...

Company Deals

Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform

Fineline Cube Jun 25, 2024

Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of...

Company Drug

J&J’s Tecvayli Earns NMPA Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jun 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it...

Posts pagination

1 … 298 299 300 … 624

Recent updates

  • Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
  • Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
  • Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
  • MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
  • Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.